Engineered immunotherapies neutralizing interleukin-22 binding protein
中和白细胞介素 22 结合蛋白的工程免疫疗法
基本信息
- 批准号:10538770
- 负责人:
- 金额:$ 19.74万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Active ImmunotherapyAcuteAdjuvantAlternative TherapiesAnti-Cytokine TherapyAnti-Inflammatory AgentsAnti-Tumor Necrosis Factor TherapyAntibodiesAntibody ResponseAntigensB-Lymphocyte EpitopesB-LymphocytesBinding ProteinsBiological ProductsCD4 Positive T LymphocytesCellsCharacteristicsChronicColitisComplementCrohn&aposs diseaseDevelopmentDiseaseDoseEngineeringEpithelialEpitopesEquilibriumExhibitsFamilyFormulationImmune responseImmunotherapyInflammationInflammation MediatorsInflammatoryInflammatory Bowel DiseasesInterleukin-10Interleukin-17Intestinal MucosaLeadListeriaMeasuresMediatingMediator of activation proteinModelingMonoclonal AntibodiesMonoclonal Antibody TherapyMusNatural regenerationPathogenesisPatientsPeptidesPharmaceutical PreparationsPhenotypePlayProductionPropertyProteinsPsoriasisRecoveryRegimenRoleSeverity of illnessSodium Dextran SulfateSymptomsSystemT cell responseT-LymphocyteT-Lymphocyte EpitopesTNF geneTherapeutic antibodiesTimeTissuesToxinTreatment EfficacyTretinoinUlcerative ColitisWorkantagonistantimicrobialbasebeta pleated sheetcombinatorialcomparative efficacycompliance behaviorcytokinedesigndextran sulfate sodium induced colitisepithelium regenerationexperienceexperimental studyhigh rewardhigh riskimprovedinnovationinterleukin-22intestinal barrierintestinal epitheliummembermouse modelmurine colitisnanofibernanomaterialsneutralizing antibodynovel strategiesnovel therapeuticspathogenic bacteriapatient populationpatient responsepre-clinicalpredicting responseregenerativeresponsescreeningtissue regenerationtreatment comparison
项目摘要
Inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, are commonly treated with
monoclonal antibodies against inflammatory cytokines. However, a large proportion of patients do not
respond to such biologics or experience diminishing efficacy over time. Additionally, episodic dosing can
exacerbate the production of anti-drug antibodies. Even in responding patients, while anti-cytokine
therapies can ameliorate disease symptoms, they often fail to induce adequate intestinal epithelial
regeneration. There is therefore a critical unmet need for an alternative therapy for inflammatory bowel
disease that generates predictable therapeutic efficacy for broad patient populations by both reducing
inflammation and promoting tissue regeneration. Active Immunotherapy, where anti-inflammatory immune
responses are generated within the patient using engineered immunogens, is an alternative but nascent
strategy that may offer improved therapeutic efficacy. This project aims to design an active immunotherapy
against a key mediator of inflammatory bowel disease, IL-22 binding protein (IL-22BP). The cytokine it
inhibits, IL-22, is a member of the IL-10 family and plays a central role in regulating the intestinal barrier in
healthy tissue and during epithelial regeneration; thus, neutralizing IL-22BP promises to facilitate the pro-
regenerative properties of IL-22 for the amelioration of IBD. Active immunotherapies will be designed using
innovative supramolecular nanomaterials designed to contain precise quantities of B-cell epitopes raising
neutralizing responses against IL-22BP and TNF, along with exogenous T-cell epitopes designed to
provide CD4+ T cell help without breaking T-cell tolerance to the native cytokines. Efficacy will be assessed
in a murine model of dextran sodium sulfate-induced colitis. If successful, this high risk/high reward project
will establish a-proof-of-concept for combinatorial active immunotherapies that are both anti-inflammatory
and regenerative in the context of IBD, constituting a first demonstration of this strategy that could have
broader application to other inflammatory diseases and cytokines.
炎症性肠病,包括溃疡性结肠炎和克罗恩病,通常用
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joel H Collier其他文献
Joel H Collier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joel H Collier', 18)}}的其他基金
Supramolecular biomaterials for tuning the inflammatory properties of the complement system
用于调节补体系统炎症特性的超分子生物材料
- 批准号:
10538835 - 财政年份:2022
- 资助金额:
$ 19.74万 - 项目类别:
Supramolecular biomaterials for tuning the inflammatory properties of the complement system
用于调节补体系统炎症特性的超分子生物材料
- 批准号:
10631187 - 财政年份:2022
- 资助金额:
$ 19.74万 - 项目类别:
Engineered immunotherapies neutralizing interleukin-22 binding protein
中和白细胞介素 22 结合蛋白的工程免疫疗法
- 批准号:
10688059 - 财政年份:2022
- 资助金额:
$ 19.74万 - 项目类别:
Sublingual Supramolecular Vaccines and Immunotherapies
舌下超分子疫苗和免疫疗法
- 批准号:
10671694 - 财政年份:2021
- 资助金额:
$ 19.74万 - 项目类别:
Supramolecular peptide immunotherapies for peanut allergy
花生过敏的超分子肽免疫疗法
- 批准号:
10416075 - 财政年份:2021
- 资助金额:
$ 19.74万 - 项目类别:
Supramolecular peptide immunotherapies for peanut allergy
花生过敏的超分子肽免疫疗法
- 批准号:
10317230 - 财政年份:2021
- 资助金额:
$ 19.74万 - 项目类别:
Sublingual Supramolecular Vaccines and Immunotherapies
舌下超分子疫苗和免疫疗法
- 批准号:
10390493 - 财政年份:2021
- 资助金额:
$ 19.74万 - 项目类别:
Engineering Adaptive Immune Responses from Hydrogel Scaffolds to Promote Tissue Regeneration
利用水凝胶支架设计适应性免疫反应以促进组织再生
- 批准号:
10571804 - 财政年份:2020
- 资助金额:
$ 19.74万 - 项目类别:
Engineering Adaptive Immune Responses from Hydrogel Scaffolds to Promote Tissue Regeneration
利用水凝胶支架设计适应性免疫反应以促进组织再生
- 批准号:
10343752 - 财政年份:2020
- 资助金额:
$ 19.74万 - 项目类别:
Engineering Adaptive Immune Responses from Hydrogel Scaffolds to Promote Tissue Regeneration
利用水凝胶支架设计适应性免疫反应以促进组织再生
- 批准号:
10117193 - 财政年份:2020
- 资助金额:
$ 19.74万 - 项目类别:
相似海外基金
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
- 批准号:
10611988 - 财政年份:2020
- 资助金额:
$ 19.74万 - 项目类别:
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
- 批准号:
10396630 - 财政年份:2020
- 资助金额:
$ 19.74万 - 项目类别:
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
- 批准号:
10210310 - 财政年份:2020
- 资助金额:
$ 19.74万 - 项目类别:
An Evaluation of Adjuvant Treatments to Mechanical Ventilation for Acute Respiratory Failure
机械通气治疗急性呼吸衰竭辅助治疗的评价
- 批准号:
319456 - 财政年份:2014
- 资助金额:
$ 19.74万 - 项目类别:
Fellowship Programs
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
- 批准号:
6566709 - 财政年份:2001
- 资助金额:
$ 19.74万 - 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
- 批准号:
6413648 - 财政年份:2000
- 资助金额:
$ 19.74万 - 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
- 批准号:
6305272 - 财政年份:1999
- 资助金额:
$ 19.74万 - 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
- 批准号:
6115194 - 财政年份:1998
- 资助金额:
$ 19.74万 - 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
- 批准号:
6276403 - 财政年份:1997
- 资助金额:
$ 19.74万 - 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
- 批准号:
6276429 - 财政年份:1997
- 资助金额:
$ 19.74万 - 项目类别: